Optimizing IFN Beta - 1B Dose
NCT00473213 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 217
Last updated 2007-05-14
Summary
BetaferonR is effective in reducing relapse rate and MRI T2-weighted lesion frequency in MS patients at the dose of 8 MIU on alternate days (THE IFNB MS Study Group, 1993). Relapse rate is reduced by 30-35% (The IFNB MS Study Group, 1993), MRI activity is decreased up to 100% in most cases (Stone et al 1995). In some patients, however, MRI activity still occurs or reappears during treatment (Stone et al 1995). MRI activity has been demonstrated to correlate with relapse occurrence (McFarland et al, 1992; Miller et al, 1996), and in some patients relapses still occur during IFN beta treatment. In other patients relapses may occur in association with the appearance, after 9-18 months of treatment, of anti-IFN beta NAB (The IFNB M S Study Group, 1995).
This protocol hypothesizes that the dose of 12 MIU BetaferonR on alternate days has more pronounced MRI and clinical effects in MS patients than that of 8 MIU. MS patients who do not respond to 8 MIU may take advantage of a higher dose. We, therefore decided to assess MRI effects after increasing the Betaferon dose (12 MIU) in RRMS patients showing a residual MRI activity (at least one new Gd enhancing lesion) during six months of standard Betaferon dose treatment (8 MIU).
Conditions
Interventions
- DRUG
-
Interferon Beta 1
Sponsors & Collaborators
-
Dimensione Ricerca s.r.l.
collaborator OTHER -
University of Turin, Italy
lead OTHER
Principal Investigators
-
Luca Durelli, Prophessor · Università degli studi di Torino-Clinica Neurologica I , Via Cherasco 15 10100 Torino
-
Antonio Carolei, M D · Ospedale Nuovo San Salvatore-Clinica Neurologica .Località Coppito.67100 L'Aquila
-
Roberto Cavallo, M.D. · Ospedale Mafggiore San Giovanni Bosco,Divisione di Neurologia Piazza Donatori del Sangue, 3 10154 Torino
-
Vittorio Cosi, Prophessor · Università degli Studi di Parma .Dipartimento di Scienze Neurologiche.Via Palestro 3 27100 Pavia
-
Luciano Deotto, M.D. · Ospedale Civile Maggiore, Divisione Neurologica, Piazzale Stefani1 37134 Verona
-
Claudio Geda, M.D. · Ospedale Civile di Chivasso.Divisione di Neurologia10034 Chivasso Torino
-
Giorgio gIULIANI, M.D · Ospedale Generale di Macerata,Servizio di Neurofisiopatologia, Via Santa Lucia 1 62100 Macerata.
-
Angelo Ghezzi, M.D. · Ospedale SAntonio Abate Servizio recupero Neurologico. Centro Studi S.M. Via Pastore 4 21013 Gallarate (VA)
-
Roberto Cotrufo, M.D. · Policlinico II Università degli Studi di Napoli. Dipartimento di Neurologia.Piazza Miraglia 2 80138 Napoli
-
Luigi Murri, Prophessor · Università degli Studi di Pisa Clinica Neurologica, Via Roma 67 56100 Pisa
-
Domenico Caputo, M.D. · Istituto Don Carlo Gnocchi Divisione Neurologica Riabilitativa. Via Capecelatro 66 20148 Milano
-
Enrico Montanari, M.D. · Ospedale Civile di Fidenza, Divisione di Neurologia Via Borghesi 1, 43036 Fidenza (Pr)
-
Franco Perla, M.D. · Ospedale S. Croce e Carle Divisione di Neurologia, Via Michele Coppino 26, 12100 Cuneo
-
Federico Piccoli, Prophessor · Università degli Studi di Palermo Istituto di Neuropsichiatria, Via Gaetano della Loggia 90129 Palermo
-
Alessandra Protti, M.D. · Ospedale Niguarda Cà Granda Divisione Neurologica, Piazza Benefattori 3, 20100 Milano
-
Giovanni Meola, Prophessor · Ospedale Clinico San Donato Neurologia, Via Morandi 30, 20097 San Donato Milanese
-
Arturo Reggio, Prophessor · Policlinico Universitario Centro Sclerosi Multipla, Via S.Sofia 78, 95185 Catania
-
MariaRosa Rottoli, M.D. · Ospedali Riuniti di Bergamo Divisione di Neurologia.Largo Barozzi.124100 Bergamo
-
Elio Scarpini, M.D · Università Degli Studi di Milano Istituto di Clinica Neurologica .Via Francesco Sforza 35 20122 Milano
-
Andrea Spissu, M.D. · Azienda Ospedaliera G. Brotzu Divisione di Neurologia. Via G. Peretti 90134 Cagliari
-
Francesco Teatini, M.D. · Ospedale Generale di Bolzano Divisione di Neurologia Via Lorenz Bohler 5 39100 Bolzano
-
Riccardo Urciuoli, M.D- · Ospedale Silvestrini Divisione di Neurologia 06156 Loc S Andrea delle Fratte Perugia
-
Luisa Motti, M.D · Centro Sclerosi Multipla Divisione di Neurologia Arcispedale S.Maria Nuova, Viale Risorgimento 57 42100 Reggio Emilia
-
Ruggero Capra, M.D. · Centro Regionale Sclerosi Multipla Piazzale Spitali Civili 1 25123 Brescia
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1999-09-30
- Completion
- 2004-02-29
More Related Trials
-
Evaluation of Emotional Disorders During Treatment by Interferon Beta in Relapsing-remitting Multiple Sclerosis Patients
NCT01201343 ·Status: COMPLETED ·Phase: PHASE4
-
Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis
NCT00489489 ·Status: COMPLETED ·Phase: PHASE2
-
The Neuroprotective Effect of Lamotrigine and Interferon Beta 1a in Patients With Relapsing-Remitting Multiple Sclerosis
NCT00917839 ·Status: UNKNOWN ·Phase: PHASE2
-
A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis
NCT03347370 ·Status: COMPLETED
-
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
NCT01252355 ·Status: TERMINATED ·Phase: PHASE3
-
A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis
NCT00883337 ·Status: COMPLETED ·Phase: PHASE3
-
BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study
NCT00185211 ·Status: COMPLETED ·Phase: PHASE3
-
National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple Sclerosis
NCT02937285 ·Status: COMPLETED ·Phase: PHASE3
-
Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta
NCT00493116 ·Status: COMPLETED ·Phase: PHASE4
-
Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron
NCT00461396 ·Status: COMPLETED
-
Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis
NCT01795872 ·Status: COMPLETED ·Phase: PHASE4
-
Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE)
NCT01706055 ·Status: COMPLETED
-
Study of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1b
NCT03408093 ·Status: COMPLETED
-
Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis
NCT00206635 ·Status: COMPLETED
-
Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis
NCT01491100 ·Status: COMPLETED
-
Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis
NCT00468182 ·Status: COMPLETED
-
Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)
NCT00313976 ·Status: WITHDRAWN ·Phase: PHASE3
-
Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)
NCT01939002 ·Status: COMPLETED ·Phase: PHASE3
-
Depression and Fatigue in MS Patients Treated With Betaferon.
NCT01354665 ·Status: COMPLETED
-
fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls
NCT00391352 ·Status: COMPLETED
-
Physical Disability in Patients Treated With Betaferon
NCT00873340 ·Status: COMPLETED
-
BENEFIT Extension Study
NCT00544037 ·Status: COMPLETED
-
A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis
NCT00441103 ·Status: COMPLETED ·Phase: PHASE3
-
REsPonse to Interferon-Alpha in InterfeRon-β Neutralizing Antibody Positive Multiple Sclerosis Patients
NCT01171209 ·Status: COMPLETED ·Phase: PHASE2
-
Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis
NCT00963833 ·Status: COMPLETED